
TVGN Stock Forecast & Price Target
TVGN Analyst Ratings
Bulls say
Tevogen Bio Holdings is taking strategic measures to increase operational control and earnings visibility by potentially acquiring a Contract Research Organization (CRO). If the acquisition is successful, Tevogen could cut costs and improve timelines in its T cell therapy pipeline while also generating additional revenue through external services. While the transaction is not guaranteed, it aligns with Tevogen's goal of implementing efficient growth strategies.
Bears say
Tevogen Bio Holdings is facing significant risks in both the short and long term, including reverse stock splits that disrupt shareholder base and lack of institutional investment following the split. The company's reliance on dilution as a means of financing and the recent decline in share price increases the overall dilution risk. Additionally, the delay in commercialization and uncertainties surrounding partnerships, financials, and legal matters pose further concerns about the company's prospects. These factors, combined with uncertainties in the market and the company's ambitious plans to build an integrated healthcare enterprise, contribute to our negative outlook on Tevogen Bio Holdings' stock.
This aggregate rating is based on analysts' research of Semper Paratus Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.
TVGN Analyst Forecast & Price Prediction
Start investing in TVGN
Order type
Buy in
Order amount
Est. shares
0 shares